GILD — Stock Film
STOCK FILMSCENE 1/11GILD · $143
Stock Expert AI presents
GILD
Gilead Sciences, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Gilead Sciences, Inc. A quick introduction.

On the stock market since 1992, it operates in the world of health and science. It has 17,000 employees. Now — the numbers.

on the stock market since 1992
17K employees
$167B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $29 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 29%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
80%Products, Other HIV
Products, Other HIV 80%Cell Therapy Products, Total Cell Therapy Product Sales 8%Trodelvy 5%Veklury 3%Other Products, Total Other product sales 3%
80% of all revenue comes from a single line: Products, Other HIV.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Every quarter, analysts set a profit bar.
How many of the last 8 did the company clear?
8 / 8
EXPECTATIONS MET OR BEATEN
8
Nov 2024
Feb 2025
Apr 2025
Aug 2025
Oct 2025
Feb 2026
May 2026
Aug 2026
8 TIMES IN THE LAST 8 QUARTERS
It clears the bar, quarter after quarter.
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
78
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
19
very weak

Clearly below the class average.

VALUATION
58
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
75
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
58
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
WEAK SPOTS
Executives aren’t buying3/10
The stock has lost its spark3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/3
A fat but narrowing margin

The net profit margin is 29% — still a thick cushion, though costs have been eating into it lately.

2
THE BRIGHT SIDE · 2/3
Delivers on expectations

It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.

3
THE BRIGHT SIDE · 3/3
Pays a steady dividend

It pays out $3.22 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
A slow sales tempo

Over the last 3 years, sales grew only 3% a year on average — the report card’s higher growth grade leans on profit power instead.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 19/100.

3
THE RISKS · 3/3
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, GILD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: GILD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film